News Image

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Provided By GlobeNewswire

Last update: Jun 27, 2025

Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Hadassah-University Medical Center, Jerusalem, Israel, as a new clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). 

Read more at globenewswire.com

CLEARMIND MEDICINE INC

NASDAQ:CMND (7/22/2025, 8:00:00 PM)

Premarket: 1.13 0 (0%)

1.13

-0.03 (-2.59%)



Find more stocks in the Stock Screener

Follow ChartMill for more